These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11289225)

  • 1. Development of a monoclonal antibody specific to a recombinant envelope protein from dengue virus type 4 expressed in Pichia pastoris.
    Pupo-Antúnez M; Rodriguez R; Alvarez M; Amin N; Rodriguez H; Otero A; Guzmán G
    Hybridoma; 2001 Feb; 20(1):35-41. PubMed ID: 11289225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice.
    Muné M; Rodríguez R; Ramírez R; Soto Y; Sierra B; Rodríguez Roche R; Marquez G; Garcia J; Guillén G; Guzmán MG
    Arch Virol; 2003 Nov; 148(11):2267-73. PubMed ID: 14579183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris.
    Tang YX; Jiang LF; Zhou JM; Yin Y; Yang XM; Liu WQ; Fang DY
    Chin Med J (Engl); 2012 Jun; 125(11):1986-92. PubMed ID: 22884066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue-1 envelope protein domain III produced in Pichia pastoris: potential use for serological diagnosis.
    Cardoso SA; Paixão VF; Oliveira MD; Honda ER; Oliveira LL; da Silva CC; De Paula SO
    Protein Expr Purif; 2013 Nov; 92(1):9-13. PubMed ID: 23993978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.
    Hiramatsu K; Tadano M; Men R; Lai CJ
    Virology; 1996 Oct; 224(2):437-45. PubMed ID: 8874504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody.
    Lai CJ; Goncalvez AP; Men R; Wernly C; Donau O; Engle RE; Purcell RH
    J Virol; 2007 Dec; 81(23):12766-74. PubMed ID: 17881450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive protection assay of monoclonal antibodies against dengue virus in suckling mice.
    Chen Z; Liu LM; Gao N; Xu XF; Zhang JL; Wang JL; An J
    Curr Microbiol; 2009 Apr; 58(4):326-31. PubMed ID: 19189182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.
    Etemad B; Batra G; Raut R; Dahiya S; Khanam S; Swaminathan S; Khanna N
    Am J Trop Med Hyg; 2008 Sep; 79(3):353-63. PubMed ID: 18784226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinant envelope protein from Dengue virus purified by IMAC is bioequivalent with its immune-affinity chromatography purified counterpart.
    Hermida L; Rodríguez R; Lazo L; López C; Márquez G; Páez R; Suárez C; Espinosa R; García J; Guzmán G; Guillén G
    J Biotechnol; 2002 Mar; 94(2):213-6. PubMed ID: 11796173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoclonal antibodies to dengue virus 4: the spectrum of the reactivity to 4 serotypes of dengue].
    Pupo Antúnez M; Alvarez Vera M; Soto Hernández M; Rodríguez Sánchez H; Rodríguez Díaz R; Morier Díaz L; Guzmán Tirado MG
    Rev Cubana Med Trop; 2000; 52(2):119-25. PubMed ID: 11107906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice.
    Delenda C; Staropoli I; Frenkiel MP; Cabanié L; Deubel V
    J Gen Virol; 1994 Jul; 75 ( Pt 7)():1569-78. PubMed ID: 8021588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes.
    León-Juárez M; García-Cordero J; Santos-Argumedo L; Romero-Ramírez H; García-Machorro J; Bustos-Arriaga J; Gutiérrez-Castañeda B; Sepúlveda NV; Mellado-Sánchez G; Cedillo-Barrón L
    APMIS; 2013 Sep; 121(9):848-58. PubMed ID: 23331315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.
    Sukupolvi-Petty S; Austin SK; Engle M; Brien JD; Dowd KA; Williams KL; Johnson S; Rico-Hesse R; Harris E; Pierson TC; Fremont DH; Diamond MS
    J Virol; 2010 Sep; 84(18):9227-39. PubMed ID: 20592088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [To evaluate the neutralizing abilities of anti-dengue virus antibodies with nonstructural protein 1 antigen capture enzyme-linked immunosorbent assay].
    Wen K; Ding YQ; Qiu LW; Pan YX; Cai JP; Yue CF; DI B; Che XY
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Aug; 43(8):680-5. PubMed ID: 20021846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris.
    Guzmán MG; Rodríguez R; Rodríguez R; Hermida L; Alvarez M; Lazo L; Muné M; Rosario D; Valdés K; Vázquez S; Martinez R; Serrano T; Paez J; Espinosa R; Pumariega T; Guillén G
    Am J Trop Med Hyg; 2003 Aug; 69(2):129-34. PubMed ID: 13677367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
    Brandriss MW; Schlesinger JJ; Walsh EE; Briselli M
    J Gen Virol; 1986 Feb; 67 ( Pt 2)():229-34. PubMed ID: 3944585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
    Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
    Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.